EQT-backed bid offers €46.50 per share cash for QIAGEN
An all-cash offer at €46.50 provides a clear near-term price target, likely pushing QGEN toward the offer price, assuming deal certainty and favorable financing and regulatory outlook.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
An all-cash offer at €46.50 provides a clear near-term price target, likely pushing QGEN toward the offer price, assuming deal certainty and favorable financing and regulatory outlook.
What happened, with direct paths to the underlying reporting
QIAGEN and EQT XI announced Crown NL Bidco B.V. will make an all-cash offer of €46.50 per QGEN share to acquire all outstanding shares. The deal signals a potential premium and possible delisting if completed, but closing depends on regulatory approvals and customary conditions, likely extending several months depending on antitrust reviews and shareholder approvals.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.